Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients – LACOG

01/03/2022

Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

Marion T van Mackelenbergh, Fenja Seither, Volker Möbus, Joyce O’Shaughnessy, Miguel Martin, Heikki Joensuu, Michael Untch, Ulrike Nitz, Guenther G Steger, Juan J Miralles, Carlos H Barrios, Masakazu Toi, Harry D Bear, Hyman Muss, Toralf Reimer, Valentina Nekljudova, Sibylle Loibl

DOI: 10.1016/j.ejca.2022.02.003

Full link: https://www.ejcancer.com/article/S0959-8049(22)00076-4/fulltext

Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

Send us a message

Cura Project

Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

Related Posts

In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”

Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)